| Similar Articles |
|---|
 |
The Motley Fool
July 6, 2007
Brian Lawler |
Medicines Decides Not to Share The Medicines Company reacquires its own drug. Until now, privately held European specialty pharma Nycomed has marketed Angiomax in Europe. Investors, take note.   |
The Motley Fool
April 2, 2008
Brian Lawler |
Medicines Company Sets Itself Apart Drugmaker Medicines Company wants to distance its angioplasty treatment from heparin. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
June 2, 2011
Kresge & Connolly |
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. |
BusinessWeek
June 9, 2009
John Carey |
Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Health
July 2007
Curt Pesmen |
Surgery to Avoid #3: Angioplasty A new study has found that heart medication is just as effective as this invasive surgery. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
Chemistry World
March 17, 2014
Phillip Broadwith |
UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
The Motley Fool
October 25, 2006
Brian Lawler |
The Medicines Company's Heartening Results At today's share price, investors are almost getting the upside associated with TMC's developmental drug pipeline for free, when combined with the sales growth and expanded opportunities available with Angiomax. That should be a hard deal to pass up for patient investors. |
Chemistry World
June 23, 2010
Sarah Houlton |
A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines. |
Pharmaceutical Executive
November 1, 2012
Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
Pharmaceutical Executive
February 1, 2014
Jill Wechsler |
Drug Coverage, Costs Under Scrutiny Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies |
The Motley Fool
January 6, 2005
Rich Duprey |
Bristol-Myers Relieves Its Headache The pharmaceutical giant is selling its consumer medicines division. Though the division represents only about 2% of Bristol-Myers' $21 billion sales, the company overall has seen sales falter and its stock decline some 12% last year. |
Chemistry World
March 18, 2013
Andrew Turley |
Interpol teams up with pharma International police service Interpol is teaming up with 29 drug companies to combat the trade in fake medicines. |
Chemistry World
April 2007
Richard Barker |
Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago. |
Pharmaceutical Executive
December 1, 2006
Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
American Family Physician
December 15, 2006 |
Tips for Using Medicines Wisely A patient guide and suggestions for safe medicine use. |
Pharmaceutical Executive
May 1, 2011
Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
